|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2008-4-14
|
|
pubmed:abstractText |
Magnetic resonance imaging (MRI) is the optimal imaging modality for the prostate and surrounding critical organ structures. However, on MRI, the titanium radioactive seeds used for brachytherapy appear as black holes (negative contrast) and cannot be accurately localized. We sought to develop an encapsulated contrast agent marker (ECAM) with high-signal intensity on MRI to permit accurate localization of radioactive seeds with MRI during and after prostate brachytherapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0360-3016
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
71
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5-8
|
|
pubmed:meshHeading |
pubmed-meshheading:18406882-Acrylates,
pubmed-meshheading:18406882-Animals,
pubmed-meshheading:18406882-Brachytherapy,
pubmed-meshheading:18406882-Cobalt,
pubmed-meshheading:18406882-Contrast Media,
pubmed-meshheading:18406882-Dogs,
pubmed-meshheading:18406882-Glass,
pubmed-meshheading:18406882-Magnetic Resonance Imaging,
pubmed-meshheading:18406882-Magnetics,
pubmed-meshheading:18406882-Male,
pubmed-meshheading:18406882-Nitrates,
pubmed-meshheading:18406882-Phantoms, Imaging,
pubmed-meshheading:18406882-Prostatic Neoplasms
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
A novel MRI marker for prostate brachytherapy.
|
|
pubmed:affiliation |
Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. sjfrank@mdanderson.org
|
|
pubmed:publicationType |
Journal Article,
Evaluation Studies
|
